PrEP Coverage

^a Unless otherwise noted, data in this web content are for adults and adolescents aged 13 and older.
^b American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the Republic of Palau, and the US Virgin Islands.
^c HIV incidence data are not available for transgender people.
^d Includes infections attributed to male-to-male sexual contact and injection drug use (men who reported both risk factors).
^e A person whose gender identity or expression is different from their assigned sex at birth.
^f A person assigned male at birth who identifies as female.
^g A person assigned female at birth who identifies as male.
^h Includes infections attributed to male-to-male sexual contact and injection drug use (men who reported both risk factors).
ⁱ The term male-to-male sexual contact is used in CDC surveillance systems. It indicates a behavior that transmits HIV infection, not how individuals self-identify in terms of their sexuality. This web content uses the term gay and bisexual men to represent gay, bisexual, and other men who reported male-to-male sexual contact.
^j Includes people who have ever had sexual contact with a person known to have, or with a risk factor for, HIV. Does not include men who have ever had sexual contact with both men and women.
^k Does not include infections attributed to male-to-male sexual contact and injection drug use (men who reported both risk factors).
^l Regions used in CDC’s National HIV Surveillance System:
Northeast: CT, ME, MA, NH, NJ, NY, PA, RI, VT
Midwest: IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, WI
South: AL, AR, DE, DC, FL, GA, KY, LA, MD, MS, NC, OK, SC, TN, TX, VA, WV
West: AK, AZ, CA, CO, HI, ID, MT, NV, NM, OR, UT, WA, WY

1. CDC. Diagnoses of HIV infection in the United States and dependent areas, 2021. HIV Surveillance Report 2023;34.
2. CDC. Estimated HIV incidence and prevalence in the United States 2017–2021. HIV Surveillance Supplemental Report 2023;28(3).
3. CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021. HIV Surveillance Supplemental Report 2023;28(4).
4. CDC. Quality of life and HIV stigma—Indicators for the National HIV/AIDS Strategy, 2022–2025, CDC Medical Monitoring Project, 2017–2020 cycles. HIV Surveillance Special Report2022;30.
5. CDC. Behavioral and clinical characteristics of persons with diagnosed HIV infection—Medical Monitoring Project, United States 2020 cycle (June 2020–May 2021). HIV Surveillance Special Report 2022;29.